SAGE Therapeutics (SAGE) Misses Q3 EPS by 9c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.31), $0.09 worse than the analyst estimate of ($2.22). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.68 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Ulta Beauty lifts guidance after Q3 results beat estimates
• Samsara Inc (IOT) Tops Q3 EPS by 3c; offers guidance
• American Woodmark (AMWD) Tops Q2 EPS by 27c; offers FY24 outlook